首页> 美国卫生研究院文献>Scientific Reports >The mGluR2 positive allosteric modulator SAR218645 improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia
【2h】

The mGluR2 positive allosteric modulator SAR218645 improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia

机译:mGluR2阳性变构调节剂SAR218645可改善与精神分裂症相关的认知症状转化模型中的记忆力和注意力缺陷

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Normalization of altered glutamate neurotransmission through activation of the mGluR2 has emerged as a new approach to treat schizophrenia. These studies describe a potent brain penetrant mGluR2 positive allosteric modulator (PAM), SAR218645. The compound behaves as a selective PAM of mGluR2 in recombinant and native receptor expression systems, increasing the affinity of glutamate at mGluR2 as inferred by competition and GTPγ35S binding assays. SAR218645 augmented the mGluR2-mediated response to glutamate in a rat recombinant mGluR2 forced-coupled Ca2+ mobilization assay. SAR218645 potentiated mGluR2 agonist-induced contralateral turning. When SAR218645 was tested in models of the positive symptoms of schizophrenia, it reduced head twitch behavior induced by DOI, but it failed to inhibit conditioned avoidance and hyperactivity using pharmacological and transgenic models. Results from experiments in models of the cognitive symptoms associated with schizophrenia showed that SAR218645 improved MK-801-induced episodic memory deficits in rats and attenuated working memory impairment in NMDA Nr1neo−/− mice. The drug reversed disrupted latent inhibition and auditory-evoked potential in mice and rats, respectively, two endophenotypes of schizophrenia. This profile positions SAR218645 as a promising candidate for the treatment of cognitive symptoms of patients with schizophrenia, in particular those with abnormal attention and sensory gating abilities.
机译:通过激活mGluR2来改变谷氨酸神经传递的正常化已成为治疗精神分裂症的一种新方法。这些研究描述了有效的脑渗透性mGluR2阳性变构调节剂(PAM),SAR218645。该化合物在重组和天然受体表达系统中起mGluR2的选择性PAM的作用,通过竞争和GTPγ 35 S结合试验可推断出谷氨酸对mGluR2的亲和力。在大鼠重组mGluR2强制偶联的Ca 2 + 动员实验中,SAR218645增强了mGluR2介导的对谷氨酸的应答。 SAR218645增强了mGluR2激动剂诱导的对侧转向。在精神分裂症阳性症状模型中测试SAR218645时,它可以降低DOI诱导的头部抽搐行为,但无法使用药理和转基因模型抑制条件性回避和过度活跃。来自与精神分裂症相关的认知症状模型的实验结果表明,SAR218645改善了MK-801诱导的大鼠发作性记忆缺陷,并减轻了NMDA Nr1 小鼠的工作记忆损伤。该药分别逆转了小鼠和大鼠的两种内表型精神分裂症的潜在潜伏抑制作用和听觉诱发电位。该图谱将SAR218645定位为治疗精神分裂症患者,尤其是注意力和感觉门控能力异常的患者的认知症状的有前途的候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号